Civica Rx, the nonprofit generic drug company formed last year by 5 health systems in order to combat drug shortages and high prices for generic drugs, added 12 additional health systems this week, bringing the total to 750 hospitals in the United States joining the venture so far.
Civica Rx, the nonprofit generic drug company formed last year by 5 health systems in order to combat drug shortages and high prices for generic drugs, added 12 additional health systems this week, bringing the total to 750 hospitals in the United States joining the venture so far.
“We are thrilled to welcome these highly-regarded health systems to Civica as founding members,” said Martin VanTrieste, Civica Rx’s chief executive officer, in a statement. “Drug shortages have become a national crisis where patient treatments and surgeries are canceled, delayed, or suboptimal. We thank these organizations for joining us to make essential generic medicines accessible and affordable in hospitals across the country.”
The aim of the initiative is to reduce costs and create a more predictable supply of many medicines.
The 12 systems joining as founding members are:
The latest members join the previously announced governing members, which include Catholic Health Initiatives, the Gary and Mary West Foundation, HCA Healthcare, Intermountain Healthcare, Laura & John Arnold Foundation, Mayo Clinic, the Peterson Center on Healthcare, Providence St. Joseph Health, SSM Health, and Trinity Health.
In 2019, Civica Rx hopes to bring over 14 hospital-administered generic drugs to hospitals and healthcare systems. Additional medications, as prioritized by the healthcare systems, will be the next phase of focus. The company is working toward becoming an FDA approved manufacturer and will either directly manufacture generic drugs or sub-contract manufacturing.
Hospitals have been struggling with drug shortages and the problem is getting worse, Martin Makary, MD, MPH, a surgical oncologist, said on a recent Managed Care Cast podcast.
Last year, the FDA decided to start extending the expiration dates of IV saline fluids in order to help hospitals cope with the shortages.
If Civica RX is successful, hospitals could see price reductions of 50%, The Chicago Tribune reported Friday. The new company will initially focus on selling to hospitals, but may eventually expand to offer products more broadly.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Health Canada Approves First Omalizumab Biosimilar
December 16th 2024Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps, based on a phase 3 study confirming its bioequivalence to the reference product.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.